Expression of the mismatch repair gene hMLH1 is enhanced in non-small cell lung cancer with EGFR mutations by Li, Mei et al.
Expression of the Mismatch Repair Gene hMLH1 Is
Enhanced in Non-Small Cell Lung Cancer with EGFR
Mutations
Mei Li1, Qiuping Zhang2, Lina Liu3, Weipeng Lu1, Hong Wei1, Rachel W. Li4, Shen Lu1*
1 Central Laboratory, The Second Hospital of Dalian Medical University, Dalian, PR China, 2 Department of Pathology, The First Hospital of Dalian Medical
University, Dalian, PR China, 3 Department of Internal Medicine, The First Hospital of Dalian Medical University, Dalian, PR China, 4  The Medical School, The
Australian Medical University, Canberra, Australia
Abstract
Mismatch repair (MMR) plays a pivotal role in keeping the genome stable. MMR dysfunction can lead to
carcinogenesis by gene mutation accumulation. HMSH2 and hMLH1 are two key components of MMR. High or low
expression of them often mark the status of MMR function. Mutations (EGFR, KRAS, etc) are common in non-small
cell lung cancer (NSCLC). However, it is not clear what role MMR plays in NSCLC gene mutations. The expression
of MMR proteins hMSH2 and hMLH1, and the proliferation markers PCNA and Ki67 were measured by
immunohistochemistry in 181 NSCLCs. EGFR and KRAS mutations were identified by high resolution melting
analysis. Stronger hMLH1 expression correlated to a higher frequency of EGFR mutations in exon 19 and 21
(p<0.0005). Overexpression of hMLH1 and the adenocarcinoma subtype were both independent factors that related
to EGFR mutations in NSCLCs (p=0.013 and p<0.0005). The expression of hMLH1, hMSH2 and PCNA increased,
while Ki67 expression significantly decreased (p=0.030) in NSCLCs with EGFR mutations. Overexpression of hMLH1
could be a new molecular marker to predict the response to EGFR-TKIs in NSCLCs. Furthermore, EGFR mutations
might be an early event of NSCLC that occur before MMR dysfunction.
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Introduction
Lung cancer is the most frequent and deadly malignant
tumor worldwide, with non-small cell lung cancer (NSCLC)
being the predominant form. Carcinogenesis of NSCLC is a
multistep process involving alterations of multiple genes
including oncogene activation and tumor suppressor gene
inactivation [1]. Recent development of new agents with
specific molecular targets, especially epidermal growth factor
receptor tyrosine kinase inhibitors (EGFR-TKIs), has enhanced
scientific interest in particular gene mutations and challenged
some of the established paradigms in the therapeutic
intervention of NSCLC [2]. The EGFR signal transduction
pathway is one of the main pathways that participate in the
mediation and regulation of cell proliferation [3]. The cells
proliferate rampantly with malignant transformation [4,5].
Approximately 30-50% of NSCLCs have mutations in key
genes, such as EGFR, KRAS, BRAF, PI3K and AKT. The two
most commonly mutated oncogenes are EGFR and KRAS
[6,7]. These gene mutations are often related to the NSCLC
patient response to molecular targeted drugs. For example,
tumors with EGFR mutations in exon 19 or 21 are often
sensitive to EGFR TKIs. In contrast, patients with mutant KRAS
tumors fail to benefit from adjuvant chemotherapy and do not
respond to EGFR inhibitors [8–10]. Interestingly, half of the
NSCLCs with the mutation in EGFR exon 19 or exon 21
produce secondary mutations in EGFR exon 20 and become
resistant to TKIs after treatment for one year [11,12]. This
indicates that the key genes of the EGFR pathway are unstable
in NSCLC. Not only is there a higher mutation frequency in
NSCLC, but also some genes like EGFR can easily produce
secondary mutations. However, it is not clear if gene mutations
in NSCLC are related to abnormalities in the DNA repair
mechanism.
Mismatch repair (MMR) is an important type of DNA repair,
playing a pivotal role in maintaining genome stability [13]. The
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hMSH2 and hMLH1 genes, which are the key components of
the MMR system, recognize and excise single-base
mismatches and insertion/deletion loops that occur during DNA
replication or DNA damage [14]. MMR dysfunction often leads
to genomic instability, including microsatellite instability (MSI)
and the accumulation of gene mutations, which are thought to
be associated with carcinogenesis of various malignant tumors
[15,16]. The dysregulation of hMLH1 or hMSH2 expression,
usually from a loss of heterozygosity (LOH) at the DNA MMR
loci, by mutation or promoter methylation, is the main reason
for MMR dysfunction [17,18]. The loss of hMLH1 or hMSH2
expression is associated with a hypermutation phenotype,
including KRAS, BRAF, APC, P53, and TGF-β mutations in
colorectal cancer [19–22]. It is not clear, however, that MMR
affects gene mutations in NSCLC. In order to study the
correlation between MMR and NSCLC mutations, we detected
EGFR and KRAS mutations and measured hMLH1, hMSH2,
PCNA and Ki67 expression in NSCLC tumors.
Materials and Methods
2.1: Ethics Statement
The study was approved by the Ethics Committee of the
Second Hospital of Dalian Medical University. All specimens in
the research were from tissue surgically removed without
affecting the diagnosis and treatment. They were collected with
the written informed consent of the patients or families before
surgery. The data were analyzed anonymously. All procedures
were in accordance with the Declaration of Helsinki.
2.2: Patients and tumor specimens
A total of 181 tumor specimens were collected from NSCLC
patients who underwent surgical procedures at the affiliated
hospitals of Dalian Medical University from 2007 to 2009. Of
these, there were 112 adenocarcinomas, 58 squamous cell
carcinomas, 4 adeno-squamous cell carcinomas, 5 large cell
carcinomas and 2 sarcomatoid carcinomas. Two certified
pathologists independently diagnosed and classified all the
patients according to the WHO classification (2004). Of the 181
patients studied, 109 were men and 72 were women with a
mean ± SD age of 62.0 ± 9.3 years (36-80 years). None of the
patients received radio- or chemotherapy before their
operations. The patients' information and histopathological
features of the tumors in this cohort are presented in Table 1.
Each tumor specimen was divided into two parts. One portion
was quickly frozen for sectioning and DNA extraction, the other
portion was formalin-fixed and paraffin-embedded for
immunohistochemistry.
Table 1. Correlation of clinicopathological parameters, immunohistochemical expression and gene mutations in NSCLC.
Variables No.
hMSH positive
(%) hMLH1 positive (%)
PCNA positive
(%)
ki67 positive
(%)
EGFR exon 19 Mutation
(%)
EGFR exon 21 Mutation
(%)
KRAS exon 2 Mutation
(%)
Age         
≤60 79 59.5 68.4 88.6 57.0 12.7 25.3 5.1
>60 102 54.9 73.5 88.2 65.7 13.7 21.6 5.9
Gender         
Female 72 54.2 79.2 90.3 55.6 20.8 a 37.5 c 0.0 b
Male 109 58.7 66.1 87.2 66.1 8.3  13.8  9.2  
Pathology         
Adc 112 56.3 77.7 a* 90.2 56.3 21.4 c 32.1 c 5.4
SCC 58 56.9 62.1  87.9 70.7 0.0  5.2  6.9
Smoking         
Non-smoking 115 56.5 78.3 b* 88.7 60.0 17.4 a 30.4 c 3.5
Smoking 66 57.6 59.1  87.9 65.2 6.1  10.6  9.1
Tumor site         
Left lung 85 55.3 76.5 88.2 57.6 17.6 18.8 8.2
Right lung 96 58.3 66.7 88.5 65.6 9.4 27.1 3.1
LN metastasis         
No 86 61.6 72.1 88.4 65.1 12.8 19.8 8.1
Yes 95 52.6 70.5 88.4 58.9 13.7 26.3 3.2
Stage         
I & II 111 61.3 74.8 91.0 61.3 16.2 23.4 5.4
III & IV 70 50.0 65.7 84.3 62.9 8.6 22.9 5.7
Adc: adenocarcinoma; SCC: squamous cell carcinoma; LN: lymph node.
a p<0.05, bp<0.01, cp<0.0005 (Pearson chi-square test).
* When smoking history was controlled, hMLH1 expression is not significantly different between Adc and SCC, p=0.267; when pathological classification was controlled, it is
different between non-smokers than smokers, p= 0.009 (CMH test).
doi: 10.1371/journal.pone.0078500.t001
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2.3: Immunohistochemical analysis
Monoclonal antibodies against human hMSH2 (1:250, clone
FE11, Invitrogen, Life technologies, USA), hMLH1 (1:50, clone
14, Invitrogen, Life technologies, USA), PCNA (1:400, clone
PC10, Thermo scientific, USA) and Ki67 (1:100, clone K-2,
Invitrogen, Life technologies, USA) were used as primary
antibodies. Biotin-streptavidin-peroxidase staining with 3, 3’-
diaminobenzidine-tetrahydrochloride (DAB) detection were
used. Immunohistochemistry was performed as previously
described [23]. Tumor cells with staining in the nuclei were
considered positive. Each slide was graded blindly according to
the percentage of positive tumor cells (0-5%, 5-10%, 10-25%,
25-50%, 50-100%) and the intensity of staining (none, weak,
moderate and strong) by two independent pathologists [24–28].
In most slides the expression intensity was related to the
expression frequency. Immunoreactivity of hMSH2, hMLH1,
PCNA and Ki67 was evaluated as negative (-), positive tumor
cells less than 25%; positive (+), 25-50% positive tumor cells;
and strong positive (++), ≥ 50% positive tumor cells.
2.4: DNA extraction and gene mutation detection
Tumor enriched areas were selected and cut from the
stained frozen sections marked by two pathologists. Genomic
DNA was extracted from these areas and purified according to
the manufacturer’s protocol (Tiangen, Beijing, China) [29,30].
KRAS exon 2 and EGFR exon 19 and 21 of each specimen
were amplified in triplicate in a 10 µL reaction volume with a 15
µL mineral oil overlay in each well of a 96-well PCR plate on a
Mastercycler (Eppendorf, German). The primers were 5'-
AGGCCTGCTGAAAATGACT-3' and 5'-
AATGGTCCTGCACCAGTAA-3' (KRAS exon 2); 5'-
TGGATCCCAGAAGGTGAGAA -3' and 5'-
AGCAGAAACTCACATCGAGGA -3' (EGFR exon 19); 5'-
CGCAGCATGTCAAGATCA -3' and 5'-
CCTCCTTACTTTGCCTCC -3' (EGFR exon 21). The reaction
conditions were as previously reported [29,30]. The mutations
were detected with high resolution melting analysis on a
LightScanner® 96 (Biofire Diagnostics, USA). The melting
curves were acquired from 60 °C to 95 °C, and analyzed using
LightScanner software (version 2.0) according to the
manufacturer’s instructions [29,30].
2.5: Statistical analysis
The Pearson chi-square test and Fisher’s exact test were
used to compare the difference of protein expression between
clinicopathological parameters. Spearman’s correlation
analysis was used to test the correlation between protein
expression. The Cochran’s and Mantel-Haenszel (CMH) test
was used to compare the difference of hMLH1 expression
between smoking status and between the tumor classifications,
with the other variable controlled. Logistic regression was used
to analyze the factors related to EGFR mutations. All of the
analyses were performed with SPSS 13.0 at the significance
level of p<0.05.
Results
3.1: Expression of hMSH2, hMLH1, PCNA and Ki67 in
NSCLCs and clinicopathological parameters
All of the proteins, hMSH2, hMLH1, PCNA and Ki67, were
expressed in the nuclei of tumor cells (Figure 1). HMSH2,
hMLH1, PCNA and Ki67 were expressed in 59.6%, 71.3%,
88.4% and 61.9% of the tumors respectively. Protein
expression between clinicopathological groups is presented in
Table 1. There was a higher frequency of hMLH1 expression in
non-smokers compared to smokers (p=0.006). Similarly, a
higher frequency of expression was observed in
adenocarcinoma compared to squamous cell carcinoma
(p=0.031). But there was no significant difference of hMLH1
expression between adenocarcinoma and squamous cell
carcinoma when the factor of smoking history was controlled
(p=0.267), while a significant difference was found when the
pathological classification was controlled (p=0.009). This
suggests that hMLH1 expression is principally affected by
smoking history, not pathological classification.
3.2: Correlation among hMSH2, hMLH1, PCNA and Ki67
expression
There were 81 cases with hMSH2 and hMLH1 co-
expression, 22 cases with only hMSH2 expression, 48 cases
with only hMLH1 expression and 30 cases without a positive
expression of either hMSH2 or hMLH1. The hMSH2 expression
was significantly correlated to the hMLH1 expression (p=0.038;
r=0.155). The expression of hMLH1 was stronger in the cases
with PCNA expression (p=0.005), but not in those with Ki67
expression (p=0.495). There was a trend of hMLH1 expression
increasing with PCNA expression (p=0.056). Expression of
hMSH2 was not correlated to the expression of either PCNA or
Ki67 (p=0.802; p=0.099) (Table 2).
3.3: KRAS and EGFR mutations in NSCLCs
Out of the 181 patients with NSCLCs, there were 10 cases
(5.5%) with a KRAS mutation and 66 cases (36.5%) with an
EGFR mutation (24 cases in exon 19 and 42 cases in exon 21)
(Figure 2). KRAS mutations were more frequent in men than in
women (p=0.008). There was no significant correlation of
KRAS mutations with other clinicopathological features (Table
1). The frequency of EGFR mutations, either in exon 19 or
exon 21, was higher in women than in men (p=0.015;
p<0.0005), in adenocarcinoma than in squamous cell
carcinoma (p<0.0005; p<0.0005), and in the non-smokers than
in smokers (p=0.031; p=0.002). There was no significant
correlation of EGFR mutations to patient age, lymph node
metastasis, tumor site or clinical stage (Table 1).
3.4: Correlation of KRAS and EGFR mutations with the
expression of hMSH2, hMLH1, PCNA and Ki67 in
NSCLC
There was no significant difference in the frequency of Ki67
or PCNA expression between NSCLCs with and without EGFR
mutation in exon 19 or exon 21 (p>0.05, Table 3). But Ki67
expression was less frequent in NSCLCs with EGFR mutations
hMLH1 Expression Enhanced in EGFR Mutation NSCLCs
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(both in exon 19 and 21) than in those without the mutations
(51.5% to 67.8%, p=0.030), but PCNA was not (85.2% to
93.9%, p=0.078).
The frequency of hMLH1 expression was higher in NSCLCs
with an EGFR exon 19 mutation than in those without the
mutation (91.7% to 68.2%, p=0.018) and in NSCLCs with an
EGFR exon 21 mutation than in those without the mutation
(88.1% to 66.2%, p=0.006). As hMLH1 expression increases
(from -, + to ++), the frequency of EGFR mutations (exon 19
and 21) were 13.2%, 38.7% and 53.0% respectively
(p<0.0005). Similar correlations were not found with hMSH2
expression (Table 3). The adenocarcinoma subtype and
hMLH1 overexpression were two independent factors that
relate to EGFR mutations (p<0.0005 and p=0.013), but gender
and smoking history do not (p=0.070 and p=0.538).
Discussion
Molecular targeting of drugs is beginning to play a more
important role in tumor treatment. To improve clinical results for
patients with NSCLC, targeted therapies are increasingly being
used with encouraging outcomes, particularly in patients with
specific molecular features [31]. EGFR and KRAS mutations
are two well-known markers that indicate the sensitivity and
resistance to EGFR-TKIs of NSCLC patients. The type of
mutation varies between ethnic groups. For example, the
frequency of EGFR mutations is higher in East Asians with
NSCLC than in Caucasians. In contrast to EGFR mutations,
KRAS mutations are found in 20-30% of Caucasians, while in
less than 10% of East Asians [29,30,32–36]. However, many
NSCLC patients do not have EGFR or KRAS mutations. So
their response to EGFR-TKIs cannot currently be predicted.
Therefore, it is necessary to find new molecular markers to
predict the response of NSCLC patients to these drugs.
Figure 1.  Protein expression of hMLH1, hMSH2, PCNA and Ki67 in NSCLCs.  Immunohistochemical profiling of hMLH1 protein
positive expression (A), hMSH2 protein positive expression (B), PCNA protein positive expression (C) and Ki67 protein positive
expression (D). (×200).
doi: 10.1371/journal.pone.0078500.g001
Table 2. Correlation of hMLH1, hMSH2, and PCNA and Ki67 expressions.
  hMSH2  PCNA  Ki67
  - + ++  - + ++  - + ++
hMLH1 - 31 4 18 a 12 21 20 b 9 28 6
 + 21 6 35  6 40 16  26 31 5
 ++ 26 4 36  3 34 29  24 30 12
hMSH2 -     9 39 30  34 36 8
 +     3 7 4  7 5 2
 ++     9 49 31  28 48 13
a p<0.05 (Spearman’s correlation analysis), Spearman’s rank correlation coefficient (r) is 0.155.
b p=0.056 (Spearman’s correlation analysis), p=0.005 (Pearson chi-square test).
doi: 10.1371/journal.pone.0078500.t002
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To the best of our knowledge, we report here for the first time
that hMLH1 expression is related to EGFR mutations in both
exon 19 and exon 21, but hMSH2 expression is not. Generally,
women and non-smoking patients with adenocarcinoma have a
relatively high probability of EGFR mutations. But lung
adenocarcinoma is common in women and non-smokers, and
most women in East Asia are non-smokers. Therefore,
clinicopathological characteristics do not predict EGFR
mutations very well. We found hMLH1 expression and
adenocarcinoma were independent factors related to EGFR
mutations. Moreover, the stronger the hMLH1 expression, the
higher EGFR mutation frequency. Gender and smoking history
were not independently correlated to EGFR mutation
frequency. It would be interesting to study the value of hMLH1
overexpression as a marker to predict the response of NSCLC
patients to EGFR-TKIs.
In previous studies, Xinarianos et al. reported that lower
hMLH1 expression was more frequent in heavy smokers [27].
HMSH2 and hMLH1 expression were also different in
adenocarcinomas compared to squamous cell carcinomas [27].
Vageli et al. evaluated the mRNA level of hMSH2 and hMLH1
in 29 primary NSCLCs and found the frequency of hMLH1
mRNA expression was higher in non-smokers than in smokers.
This study also found that there were differences in the
expression pattern of hMLH1 and hMSH2 between
adenocarcinoma and squamous cell carcinoma [37,38]. Wang
et al. found that there was more hMLH1 and hMSH2
expression in NSCLC samples from women than in those from
men [39]. We found hMLH1 expression was higher in patients
Figure 2.  EGFR, KRAS mutation detection with high resolution melting analysis.  Different melting curves showing mutation
type (red line) relative to wild type (grey line) of KRAS exon 2 (a), EGFR exon 19 (b) and EGFR exon 21 (c). Every sample was
analyzed in triplicate. The data was plotted directly (A) or the wild type was chosen as a horizontal base line (B).
doi: 10.1371/journal.pone.0078500.g002
Table 3. Correlation of hMSH2, hMLH1, PCNA and Ki67 expression with KRAS and EGFR mutations.
 n hMSH2 (%) hMLH1 (%) PCNA (%) Ki67 (%)
KRAS M 10 60.0 80.0 80.0 40.0
 W 171 56.7 70.8 88.9 63.2
EGFR exon 19 M 24 70.8 91.7 a 95.8 45.8
 W 157 54.8 68.2  87.3 64.3
EGFR exon 21 M 42 52.4 88.1 b 92.9 54.8
 W 139 58.3 66.2  87.1 64.0
M: mutation, W: wild type.
a p<0.05, b p<0.01 (Pearson chi-square test or Fisher’s exact test).
doi: 10.1371/journal.pone.0078500.t003
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without smoking history. But it was not different between
adenocarcinoma and squamous cell carcinoma and between
genders, when we adjusted with the factor of smoking history.
It suggests that smoking could be a major factor that affects
hMLH1 expression. Saletta et al. and Vogelsang et al.
independently found that exposure to tobacco smoke
inactivates MMR function by inducing chromosomal instability
and polymorphisms of the hMLH1 gene [40,41].
Both PCNA and Ki67 can be used to indicate the status of
cell proliferation. PCNA is stimulated in the process of MMR as
a necessary component [21], while Ki67 not. In this study, we
found cases with EGFR mutations have a higher frequency of
both hMLH1 and PCNA expression, but a trend toward lower
Ki67 expression. This suggests that an EGFR mutation might
stimulate and initiate the process of DNA repair by increasing
hMLH1 and PCNA expression, and then prolong the cell cycle.
Therefore, EGFR mutations in NSCLCs would activate the
MMR function, instead of being the result of genomic instability
caused by MMR dysfunction. EGFR mutations might be an
early event in the carcinogenesis of NSCLC before MMR
dysfunction.
In addition, Kouso et al. demonstrated the independence of
hMSH2 and hMLH1 expression with different roles in NSCLC
[28]. Besides a role in the process of MMR as a key
component, the hMLH1 protein also interacts with other DNA
repair and apoptosis signaling molecules such as PCNA,
BRCA1, P53 and ATM [42–45]. Therefore, hMLH1 might be
also regulated by other factors. An et al. and Shih et al.
reported that specific polymorphisms of hMLH1 are related to
the susceptibility and prognosis of lung cancer and occurred
more often in lung squamous cell carcinoma than in
adenocarcinoma [46,47]. All of these factors could lead to
imbalance of hMSH2 and hMLH1 expression. Moreover,
hMSH2 and hMLH1 expression can vary not only between
different histological origins, but also between different ethnic
groups [32–36].
In summary, EGFR mutations in exon 19 and 21 correlate
with MMR dysfunction in NSCLC. Overexpression of hMLH1
could be a new marker for patient sensitivity to EGFR-TKIs. In
the past, MMR dysfunction has been assumed to cause EGFR
mutations. However, EGFR mutations could also increase
hMLH1 overexpression as a compensatory mechanism. A
cause-effect relationship has not been established either way.
Further studies would be required to provide further insight into
which event occurs first. In other case, the possibility of using
hMLH1 as an indicator of TKI responses may prove useful.
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